The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)
M Bauckneht, SE Rebuzzi, A Signori… - European journal of …, 2022 - Springer
Purpose To combine peripheral blood indices and clinical factors in a prognostic score for
metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 …
metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 …
Patient selection for radium-223 therapy in patients with bone metastatic castration-resistant prostate cancer: new recommendations and future perspectives
MJ van der Doelen, N Mehra, R Hermsen… - Clinical genitourinary …, 2019 - Elsevier
Radium-223 therapy was registered in 2013 as a new life-prolonging therapeutic option for
patients with symptomatic bone metastatic castration-resistant prostate cancer after the …
patients with symptomatic bone metastatic castration-resistant prostate cancer after the …
Real-world outcomes and factors predicting survival and completion of radium 223 in metastatic castrate-resistant prostate cancer
S Parikh, L Murray, L Kenning, D Bottomley, O Din… - Clinical Oncology, 2018 - Elsevier
Aims To analyse outcomes in metastatic castrate-resistant prostate cancer (mCRPC)
patients treated with radium 223 (Ra-223) across the Yorkshire and Humber Cancer …
patients treated with radium 223 (Ra-223) across the Yorkshire and Humber Cancer …
The role of PET and SPECT imaging in prostate cancer targeted alpha therapy: when and how?
V Frantellizzi, M Ricci, A Cimini, L Filippi, M Conte… - Applied Sciences, 2023 - mdpi.com
This review discusses the current state of Targeted Alpha Therapy (TAT) in prostate cancer,
particularly in mCRPCT (metastatic castration-resistant prostate cancer). This review …
particularly in mCRPCT (metastatic castration-resistant prostate cancer). This review …
Role of baseline and post-therapy 18F-FDG PET in the prognostic stratification of metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium …
M Bauckneht, S Capitanio, MI Donegani, E Zanardi… - Cancers, 2019 - mdpi.com
Radium-223 dichloride (Ra223) represents the unique bone-directed treatment option that
shows an improvement in overall survival (OS) in metastatic castrate resistant prostate …
shows an improvement in overall survival (OS) in metastatic castrate resistant prostate …
The prognostic role of baseline metabolic tumor burden and systemic inflammation biomarkers in metastatic castration-resistant prostate cancer patients treated with …
M Bauckneht, SE Rebuzzi, A Signori, MI Donegani… - Cancers, 2020 - mdpi.com
Simple Summary Radium-223 is an alpha-emitting radioisotope that selectively binds to
increased bone turnover areas, such as metastatic sites, acting as a bone-seeking calcium …
increased bone turnover areas, such as metastatic sites, acting as a bone-seeking calcium …
Radium‑223 in patients with metastatic castration‑resistant prostate cancer: Efficacy and safety in clinical practice
A Prelaj, SE Rebuzzi, F Buzzacchino… - Oncology …, 2019 - spandidos-publications.com
Radium‑223 has improved overall survival (OS) and reduced symptomatic skeletal events
(SSE) in patients with metastatic castration‑resistant prostate cancer (mCRPC) and bone …
(SSE) in patients with metastatic castration‑resistant prostate cancer (mCRPC) and bone …
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
MJ van der Doelen, A Stockhaus, Y Ma… - European Journal of …, 2021 - Springer
Purpose Radium-223 is a life-prolonging therapy for castration-resistant prostate cancer
(CRPC) patients with symptomatic bone metastases. However, validated biomarkers for …
(CRPC) patients with symptomatic bone metastases. However, validated biomarkers for …
Narrative medicine in metastatic prostate cancer reveals ways to improve patient awareness & quality of care
G De Vincentis, F Monari, S Baldari, M Salgarello… - Future …, 2018 - Taylor & Francis
Aim: To describe the journey of patients with metastatic castration-resistant prostate cancer
(mCRPC) in treatment with radium-223. Methods: A multiperspective analysis was …
(mCRPC) in treatment with radium-223. Methods: A multiperspective analysis was …
223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice
S Dizdarevic, M Jessop, P Begley, S Main… - European Journal of …, 2018 - Springer
Purpose We first assessed whether the pattern of referrals to a nuclear medicine clinic
improved as experience with 223 Ra-dichloride increased, and whether referral patterns …
improved as experience with 223 Ra-dichloride increased, and whether referral patterns …